A catalyst for collaborative advances in cancer immunotherapy
On 16th of February, Dr Frederick Thielen represented ASCERTAIN at the 6th European CAR T-cell Meeting. His journey began by attending the meeting of the T2EVOLVE consortium, an EU-funded initiative pioneering collaboration between leading scientists and industry in cancer immunotherapy. This ground-breaking alliance aims to accelerate the development, raise awareness, and improve access to immunotherapies, in particular using genetically engineered T cell receptors (TCRs) or synthetic chimeric antigen receptors (CARs). ASCERTAIN’s collaboration with T2EVOLVE underscores our commitment to improving access to novel therapies such as CAR T-cell therapy.
During the CAR T-cell meeting, Frederick presented ASCERTAIN in a session dedicated to European projects and networks, emphasising the central role of collaboration in advancing CAR T-cell therapy. His presentation generated lively interest in ASCERTAIN, sparking dynamic discussions and fostering connections with researchers from various European projects that paved the way for potential collaborations. The ASCERTAIN team looks forward to further exploring these collaborative opportunities to drive innovation in cancer treatment.
You can gain further insights into the project in the interview with Frederick:
